OBJECTIVES: To assess outcomes over the first 7 years of antiretroviral therapy (ART) at Themba Lethu Clinic, Johannesburg, South Africa. DESIGN: Observational cohort study. METHODS: Patients are managed according to South African National Treatment Guidelines. Mortality is ascertained through linkage with the national vital registration system. Loss to follow-up is defined as at least 3 months late for the last scheduled appointment. RESULTS: Between April 2004 and March 2010, 13 227 patients initiated ART, increasing from 1794 in the year 2004/2005 to 2481 in 2009/2010. Median CD4 cell count at ART initiation increased 39% between 2004 and 2009 (82 vs. 114 cells/ml). The proportion who died within 1 year on ART was below 11% at all time points, whereas the proportion lost by 1 year increased from 8.5% in 2004 to 12.1% in 2009 [risk ratio (RR) 1.42, 95% confidence interval (CI) 1.18–1.71]. We followed the 1794 patients initiated in April 2004 and March 2005 through August 2011 for 8172 person-years. We estimated 25% of patients were lost and 16% died. The overall mortality rate was 3.59 per 100 person-years (95% CI 3.20–4.02). Of the 1577 who completed at least 6 months of follow-up, 213 (13.5%) failed first-line treatment in a median (interquartile range) of 25.9 (15.8–41.4) months on treatment. Of those who failed, 141 (66.2%) switched to second-line for a rate of 48.5 per 100 person-years (95% CI 41.1–57.2). CONCLUSION: Despite some improvements over 7 years, more intervention is needed in the first year on treatment to reduce overall attrition.
OBJECTIVES: To assess outcomes over the first 7 years of antiretroviral therapy (ART) at Themba Lethu Clinic, Johannesburg, South Africa. DESIGN: Observational cohort study. METHODS:Patients are managed according to South African National Treatment Guidelines. Mortality is ascertained through linkage with the national vital registration system. Loss to follow-up is defined as at least 3 months late for the last scheduled appointment. RESULTS: Between April 2004 and March 2010, 13 227 patients initiated ART, increasing from 1794 in the year 2004/2005 to 2481 in 2009/2010. Median CD4 cell count at ART initiation increased 39% between 2004 and 2009 (82 vs. 114 cells/ml). The proportion who died within 1 year on ART was below 11% at all time points, whereas the proportion lost by 1 year increased from 8.5% in 2004 to 12.1% in 2009 [risk ratio (RR) 1.42, 95% confidence interval (CI) 1.18–1.71]. We followed the 1794 patients initiated in April 2004 and March 2005 through August 2011 for 8172 person-years. We estimated 25% of patients were lost and 16% died. The overall mortality rate was 3.59 per 100 person-years (95% CI 3.20–4.02). Of the 1577 who completed at least 6 months of follow-up, 213 (13.5%) failed first-line treatment in a median (interquartile range) of 25.9 (15.8–41.4) months on treatment. Of those who failed, 141 (66.2%) switched to second-line for a rate of 48.5 per 100 person-years (95% CI 41.1–57.2). CONCLUSION: Despite some improvements over 7 years, more intervention is needed in the first year on treatment to reduce overall attrition.
Authors: Bruce A Larson; Alana Brennan; Lynne McNamara; Lawrence Long; Sydney Rosen; Ian Sanne; Matthew P Fox Journal: Bull World Health Organ Date: 2010-04-16 Impact factor: 9.408
Authors: Alana T Brennan; Lawrence Long; Mhairi Maskew; Ian Sanne; Imogen Jaffray; Patrick MacPhail; Matthew P Fox Journal: AIDS Date: 2011-10-23 Impact factor: 4.177
Authors: Andrew Boulle; Gilles Van Cutsem; Katherine Hilderbrand; Carol Cragg; Musaed Abrahams; Shaheed Mathee; Nathan Ford; Louise Knight; Meg Osler; Jonny Myers; Eric Goemaere; David Coetzee; Gary Maartens Journal: AIDS Date: 2010-02-20 Impact factor: 4.177
Authors: Elena Losina; Ingrid V Bassett; Janet Giddy; Senica Chetty; Susan Regan; Rochelle P Walensky; Douglas Ross; Callie A Scott; Lauren M Uhler; Jeffrey N Katz; Helga Holst; Kenneth A Freedberg Journal: PLoS One Date: 2010-03-04 Impact factor: 3.240
Authors: Lawrence Long; Alana Brennan; Matthew P Fox; Buyiswa Ndibongo; Imogen Jaffray; Ian Sanne; Sydney Rosen Journal: PLoS Med Date: 2011-07-19 Impact factor: 11.069
Authors: Neo Christopher Chung; Carolyn Bolton-Moore; Roma Chilengi; Margaret P Kasaro; Jeffrey S A Stringer; Benjamin H Chi Journal: Trop Med Int Health Date: 2017-01-19 Impact factor: 2.622
Authors: Nicole L De La Mata; Penh S Ly; Kinh V Nguyen; Tuti P Merati; Thuy T Pham; Man P Lee; Jun Y Choi; Jeremy Ross; Matthew G Law; Oon T Ng Journal: J Acquir Immune Defic Syndr Date: 2017-04-15 Impact factor: 3.731
Authors: William B MacLeod; Jacob Bor; Sue Candy; Mhairi Maskew; Matthew P Fox; Katia Bulekova; Alana T Brennan; James Potter; Cornelius Nattey; Dorina Onoya; Koleka Mlisana; Wendy Stevens; Sergio Carmona Journal: BMJ Open Date: 2022-10-19 Impact factor: 3.006
Authors: Robert Gross; Scarlett L Bellamy; Bakgaki Ratshaa; Xiaoyan Han; Andrew P Steenhoff; Mosepele Mosepele; Gregory P Bisson Journal: Addiction Date: 2016-09-07 Impact factor: 6.526
Authors: Sydney Rosen; Bruce Larson; Julia Rohr; Ian Sanne; Constance Mongwenyana; Alana T Brennan; Omar Galárraga Journal: AIDS Date: 2014-01-28 Impact factor: 4.177